

Defining the Mode of Action of Tetramic Acid Antibacterials Derived from *Pseudomonas aeruginosa* Quorum Sensing Signals

Colin A. Lowery,^{†,‡} Junguk Park,^{†,‡} Christian Gloeckner,^{†,‡} Michael M. Meijler,^{†,‡,&}
 Ryan S. Mueller,[§] Helena I. Boshoff,^{||} Ricky L. Ulrich,^{⊥,▽} Clifton E. Barry, III,^{||}
 Douglas H. Bartlett,[§] Vladimir V. Kravchenko,[‡] Gunnar F. Kaufmann,^{*,†,‡} and
 Kim D. Janda^{*,†,‡,#}

The Skaggs Institute for Chemical Biology and Departments of Chemistry, Immunology & Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, Marine Biology Research Division, Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California-San Diego, La Jolla, California 92037, Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21704, and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Received July 8, 2009; E-mail: kaufmann@scripps.edu; kjjanda@scripps.edu

Abstract: In nature, bacteria rarely exist as single, isolated entities, but rather as communities comprised of many other species including higher host organisms. To survive in these competitive environments, microorganisms have developed elaborate tactics such as the formation of biofilms and the production of antimicrobial toxins. Recently, it was discovered that the Gram-negative bacterium *Pseudomonas aeruginosa*, an opportunistic human pathogen, produces an antibiotic, 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione (C₁₂-TA), derived from one of its quorum sensing molecules. Here, we present a comprehensive study of the expanded spectrum of C₁₂-TA antibacterial activity against microbial competitors encountered by *P. aeruginosa* in nature as well as significant human pathogens. The mechanism of action of C₁₂-TA was also elucidated, and C₁₂-TA was found to dissipate both the membrane potential and the pH gradient of Gram-positive bacteria, correlating well with cell death. Notably, in stark contrast to its parent molecule 3-oxo-dodecanoyl homoserine lactone (3-oxo-C₁₂-HSL), neither activation of cellular stress pathways nor cytotoxicity was observed in human cells treated with C₁₂-TA. Our results suggest that the QS machinery of *P. aeruginosa* has evolved for a dual-function, both to signal others of the same species and also to defend against host immunity and competing bacteria. Because of the broad-spectrum antibacterial activity, established mode of action, lack of rapid resistance development, and tolerance by human cells, the C₁₂-TA scaffold may also serve as a new lead compound for the development of antimicrobial therapeutics.

Introduction

To exist in a world with limited resources, microorganisms have developed elegant survival mechanisms that often act at the expense of other competitors, including bacteria. These tactics encompass highly specialized iron uptake systems, the formation of sessile communities known as biofilms, and the

production of toxins against both microbial organisms and eukaryotic hosts. By harnessing the conflict that occurs among these microorganisms, however, a plethora of new antimicrobial therapeutics has been discovered via the exploitation of the chemical agents used in this bacterial warfare. In fact, natural products directly from bacterial sources or their semisynthetic derivatives account for the majority of currently employed antibiotics and, as a result of the rich environmental diversity inhabited by microorganisms, comprise a vast structural and mechanistic landscape.¹ One class of natural products that has attracted considerable attention is the tetramic acids and their derivatives, due to their structural complexity and diversity as well as their broad spectrum of biological activity.²

[†] The Skaggs Institute for Chemical Biology and Department of Chemistry, The Scripps Research Institute.

[‡] Department of Immunology & Microbial Science, The Scripps Research Institute.

[§] Scripps Institution of Oceanography, University of California-San Diego.

^{||} National Institute of Allergy and Infectious Diseases.

[⊥] United States Army Medical Research Institute of Infectious Diseases.

[#] Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute.

[&] Current address: Department of Chemistry, Ben-Gurion University of Negev, Be'er Sheva, Israel.

[▽] Current address: Hagerstown Community College, Hagerstown, MD.

(1) Clardy, J.; Fischbach, M. A.; Walsh, C. T. *Nat. Biotechnol.* **2006**, *24*, 1541–50.

(2) Royles, B. J. L. *Chem. Rev.* **1995**, *95*, 1981–2001.




Figure 1. Conversion of 3-oxo-AHLs to the corresponding TA compounds.

Tetramic acids (TAs) are a class of compounds containing a 2,4-pyrrolidinedione ring system with biological activities ranging from antibacterial and antiviral to mycotoxic, fungicidal, as well as anticancer properties.² Recently, during our efforts to generate monoclonal antibodies against bacterial acyl homoserine lactones, we uncovered the conversion of 3-oxo-dodecaonyl homoserine lactone (3-oxo-C₁₂-HSL), an intercellular signaling molecule used by *P. aeruginosa*, to the tetramic acid 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione (C₁₂-TA) through an irreversible, nonenzymatic Claisen-like reaction (Figure 1).^{3,4} Both this tetramic acid and its parent homoserine lactone exhibited antibacterial activity against selected Gram-positive strains, with C₁₂-TA exhibiting significantly more potent antibacterial activity than 3-oxo-C₁₂-HSL.⁴

P. aeruginosa is a common environmental Gram-negative bacterium that has become an opportunistic human pathogen because of the ability to take advantage of weaknesses in the host immune system. The intercellular communication mediated by 3-oxo-C₁₂-HSL, a process known as quorum sensing (QS), is crucial to the pathogenicity of *P. aeruginosa*, controlling such functions as virulence factor production, iron acquisition, and biofilm formation.^{5,6} However, recent reports have suggested that this signal imparts benefits beyond communication, as mutants arise during chronic *P. aeruginosa* infections that exhibit a loss of function in the gene encoding the 3-oxo-C₁₂-HSL receptor, while the HSL synthase remains active.^{5,7–12} With this in mind, we hypothesized that 3-oxo-C₁₂-HSL, via the action of C₁₂-TA, might be used by *P. aeruginosa* as a strategy to hamper encroachment by competing bacteria;⁴ herein, we define the antimicrobial properties of tetramic acids to

Table 1. Antibacterial Activity of C₁₂- and C₁₄-TA^a

bacteria	C ₁₂ -TA EC ₅₀ , μg/mL (μM)	C ₁₂ -TA MIC, μg/mL	C ₁₄ -TA MIC, μg/mL
Gram-Positive			
<i>B. anthracis</i> Ames strain	n.d.	54	n.d.
<i>B. cereus</i> PCI 213	2.4 (8.3)	12.5	3.12
<i>B. subtilis</i> Marburg	n.d.	25	3.12
<i>C. diphtheriae</i> 48255	8.9 (30.1)	25	6.25
<i>E. faecalis</i> NCTC 775	10.0 (33.7)	50	6.25
<i>L. plantarum</i> NCIMB 8826	n.d.	25	12.5
<i>M. tuberculosis</i> H37Rv	0.71 (2.38)	5	2.5
<i>S. aureus</i> USA-300	n.d.	25	6.25
<i>S. aureus</i> Wood 46	8.0 (26.7)	25	6.25
Gram-Negative			
<i>B. cepacia</i> UCB 717	>30 (>100)	n.d.	n.d.
<i>E. coli</i> K12	>30 (>100)	n.d.	n.d.
<i>E. coli</i> D22	10.7 (35.9)	50	25
<i>E. coli</i> Δimp	5.7 (19.2)	25	12.5
<i>H. influenzae</i> AMC 36-A-1	23.4 (78.5)	n.d.	n.d.
<i>P. aeruginosa</i> PAO-1	>30 (>100)	n.d.	n.d.
<i>V. cholerae</i> N16961	11.2 (37.7)	>100	>100
<i>V. cholerae</i> TP	9.1 (30.4)	100	100
<i>V. harveyi</i> BB120	21.6 (72.6)	100	6.25

^a n.d. = not determined.

include several relevant human pathogens and known natural competitors of *P. aeruginosa*. We also demonstrate the failure of *S. aureus* to develop resistance to C₁₂-TA after 20 passages, as well as the lack of cytotoxicity against human cells. Moreover, the mode of action of C₁₂-TA was elucidated by focusing on four Gram-positive bacteria: *Bacillus cereus*, *Bacillus subtilis*, *Enterococcus faecalis*, and *Staphylococcus aureus*, each showing varying degrees of susceptibility toward C₁₂-TA.

Results

C₁₂-TA Is Cytotoxic Against Bacterial Competitors and Clinically Relevant Pathogens. To elucidate the antibacterial activity of 3-oxo-AHL-derived tetramic acids, we examined the activity of C₁₂- and C₁₄-TA against several bacteria, both Gram-positive and -negative species, potentially encountered by *P. aeruginosa* in natural environments as well as several important human pathogens. Although the C₁₄-AHL is not one of the major signals of *P. aeruginosa*, we included C₁₄-TA for comparison, and in each case, the minimum inhibitory concentration (MIC) of C₁₄-TA is slightly more potent than that of C₁₂-TA, likely due to the increased hydrophobicity of the longer acyl chain allowing for better membrane partitioning or cell penetration. Especially noteworthy is the activity of C₁₂- and C₁₄-TA against *Bacillus anthracis* and the community acquired methicillin resistant strain of *Staphylococcus aureus* (a USA-300 clone). Additionally, both C₁₂- and C₁₄-TA exhibit potent activity against *Mycobacterium tuberculosis*, the causative agent of tuberculosis (Table 1). As a result, these data give credence to our proposition of C₁₂-TA as a new antibiotic scaffold for future drug development efforts. *M. tuberculosis* and *Corynebacterium diphtheriae* represent members of the phylum Actinobacteria, whereas the other Gram-positive bacteria previously examined are members of the phylum Firmicutes. Members of these two phyla differ based on their DNA composition, but all share a common feature in the absence of an outer membrane. This fundamental difference between Gram-negative and -positive bacteria is likely the origin of the selective cytotoxicity of C₁₂-TA. Gram-negative bacteria possess an outer membrane composed of lipopolysaccharide (LPS) or -oligosaccharide (LOS),

- (3) Kaufmann, G. F.; Sartorio, R.; Lee, S. H.; Mee, J. M.; Altobelli, L. J., III.; Kujawa, D. P.; Jeffries, E.; Clapham, B.; Meijler, M. M.; Janda, K. D. *J. Am. Chem. Soc.* **2006**, *128*, 2802–3.
- (4) Kaufmann, G. F.; Sartorio, R.; Lee, S. H.; Rogers, C. J.; Meijler, M. M.; Moss, J. A.; Clapham, B.; Brogan, A. P.; Dickerson, T. J.; Janda, K. D. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 309–14.
- (5) Heurlier, K.; Denervaud, V.; Haas, D. *Int. J. Med. Microbiol.* **2006**, *296*, 93–102.
- (6) Geske, G. D.; O'Neill, J. C.; Blackwell, H. E. *Chem. Soc. Rev.* **2008**, *37*, 1432–47.
- (7) Cabrol, S.; Olliver, A.; Pier, G. B.; Andremont, A.; Ruimy, R. *J. Bacteriol.* **2003**, *185*, 7222–30.
- (8) Favre-Bonte, S.; Chamot, E.; Kohler, T.; Romand, J. A.; van Delden, C. *BMC Microbiol.* **2007**, *7*, 33.
- (9) Lee, B.; Haagenen, J. A.; Ciofu, O.; Andersen, J. B.; Hoiby, N.; Molin, S. *J. Clin. Microbiol.* **2005**, *43*, 5247–55.
- (10) Schaber, J. A.; Carty, N. L.; McDonald, N. A.; Graham, E. D.; Cheluvappa, R.; Griswold, J. A.; Hamood, A. N. *J. Med. Microbiol.* **2004**, *53*, 841–53.
- (11) Sandoz, K. M.; Mitzimberg, S. M.; Schuster, M. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 15876–81.
- (12) Diggle, S. P.; Griffin, A. S.; Campbell, G. S.; West, S. A. *Nature* **2007**, *450*, 411–4.




Figure 2. Structures of C₁₂-TA and reutericyclin. The 2,4-pyrrolidinedione ring system characteristic of TA compounds is shown in red.

phospholipids, and proteins, providing a permeability barrier that is absent in Gram-positive bacteria, in which the bacterial cell wall is composed of a thicker peptidoglycan layer.⁴

Although there is a general trend of insensitivity of Gram-negative strains to C₁₂-TA, our studies revealed that *Vibrio* spp., including two strains of the important human pathogen *V. cholerae*,¹³ are in fact susceptible to C₁₂-TA. The reasoning for this may lie in the difference in LPS glycosylation pattern in the outer membrane of *Vibrio* spp. as compared to other Gram-negative bacteria. The outer membrane of *V. cholerae* has also been shown to be particularly permeable to hydrophobic compounds as compared to other Gram-negative strains.¹⁴ Likewise, *Hemophilus influenzae*, which has an outer membrane composed of lipooligosaccharide units rather than the longer LPS units of other Gram-negative bacteria,¹⁵ was found to be sensitive to C₁₂-TA.

To uncover how the outer membrane modulates Gram-negative bacterial resistance toward C₁₂-TA, we examined two LPS defective *E. coli* strains: D22 and a Δimp (increased membrane permeability gene) mutant.^{16,17} The D22 strain, which possesses an *envA* mutation resulting in impaired lipid A biosynthesis, and the Δimp mutant, which exhibits abnormal assembly of LPS at the cell surface, both have compromised outer membranes as a result of these defects in LPS biogenesis.^{18,19} Indeed, these two strains have been used to monitor the effects of detergents and other hydrophobic organic compounds normally ineffective against Gram-negative bacteria.^{20,21} We reasoned that they would be sensitive to the antibacterial effects of C₁₂- and C₁₄-TA, and this was found to be the case. Because of the differential activity between Gram-positive and -negative strains, as well as its effectiveness against *Vibrio* spp. and membrane-defective *E. coli* strains, we predicted the bacterial membrane as the target of antibacterial activity of C₁₂-TA.

C₁₂-TA Interferes with the Bacterial Proton Gradient and Membrane Potential. Naturally occurring tetramic acid derivatives are of great interest because of their broad spectrum of antibacterial activity. Interestingly, a structurally related tetramic acid antibiotic, reutericyclin (Figure 2), has been shown to act

as an ionophore against Gram-positive bacteria.^{22,23} Reutericyclin selectively imports protons into *Lactobacilli* spp., thereby eliminating the proton motive force (PMF) of the cell through dissipation of the transmembrane proton gradient (ΔpH), ultimately culminating in cell death. The PMF is vital to cell survival, as it is used to generate energy for functions such as ATP synthesis and solute transport. Bacteria ultimately use two electrochemical gradients to maintain the PMF, the membrane potential ($\Delta\Psi$) and the proton gradient (ΔpH), and, accordingly, we evaluated the mechanism of action of C₁₂-TA by assessing its effects on these two membrane gradients.

The capacity of C₁₂-TA to disrupt the $\Delta\Psi$ was measured using the fluorescent probe DiSC₃(5). The cationic nature of DiSC₃(5) allows the dye to accumulate inside cells with polarized membranes, where its fluorescence is quenched by aggregation with other DiSC₃(5) molecules. Upon depolarization of the membrane, the probe is released and fluorescence is restored; that is, an increase in emission corresponds to a depolarization of the membrane. Treatment of DiSC₃(5)-loaded *B. cereus* with C₁₂-TA resulted in a dose-dependent increase in fluorescence with an EC₅₀ value of $49.0 \pm 2.0 \mu M$ (Figure 3A). To correlate membrane depolarization with cytotoxicity, the effects of C₁₂-TA on cultures of *B. cereus* (OD₆₀₀ = 0.4) were determined, and dose-dependent cytotoxicity was observed with an EC₅₀ of $53.6 \pm 3.7 \mu M$ (Figure 3A). $\Delta\Psi$ is maintained due in large part to the maintenance of K⁺ gradients across the cell membrane,²⁴ and indeed, when *B. cereus* was incubated with C₁₂-TA and varying concentrations of KCl in HEPES buffer, the extent of depolarization varied with the concentration of K⁺. When performed in K⁺-free HEPES buffer, $\Delta\Psi$ was still diminished, implicating the transport of other ions across the membrane by C₁₂-TA (data not shown).

Another ion used in the maintenance of the PMF is the proton, which is responsible for the chemical gradient across the membrane (ΔpH). The effect of C₁₂-TA on the transmembrane ΔpH was measured using the fluorescent probe cFDA-SE, which is internalized by the bacteria and becomes sensitive to fluctuations in pH. Figure 3B shows the decrease of the internal pH (open symbols), and thus the ΔpH of *B. cereus*, with increasing concentrations of C₁₂-TA (EC₅₀ = $61.6 \pm 8.7 \mu M$). This value also corresponds closely to the EC₅₀ for cell death and implicates the loss of this gradient in the death of the cell. Similar results also were observed for three other Gram-positive bacteria: *B. subtilis*, *Enterococcus faecalis*, and *S. aureus* (Table 2). In the case of *S. aureus* and *E. faecalis*, the effect on ΔpH was observed at lower concentrations than that required for cell death, which may be indicative of a lower contribution of the ΔpH to the overall PMF under these growth conditions.

It is worth noting that the EC₅₀ values reported for the PMF disruption are higher than the EC₅₀ values reported for growth inhibition in Table 1. This increase in values can be attributed to the difference in the two assays, in that the values in Table 1 represent growth inhibition, whereas the values measured in the mechanistic studies represent the concentration needed to kill bacterial cultures at an OD₆₀₀ of 0.4. Thus, the lethal concentrations needed to kill dense cultures were evaluated for

(13) Purdy, A.; Rohwer, F.; Edwards, R.; Azam, F.; Bartlett, D. H. *J. Bacteriol.* **2005**, *187*, 2992–3001.

(14) Chatterjee, A.; Chaudhuri, S.; Saha, G.; Gupta, S.; Chowdhury, R. *J. Bacteriol.* **2004**, *186*, 6809–14.

(15) Gilsdorf, J. R. *Infect. Immun.* **1998**, *66*, 5053–9.

(16) Normark, S.; Boman, H. G.; Mattsson, E. *J. Bacteriol.* **1969**, *97*, 1334–42.

(17) Sampson, B. A.; Misra, R.; Benson, S. A. *Genetics* **1989**, *122*, 491–501.

(18) Ruiz, N.; Gronenberg, L. S.; Kahne, D.; Silhavy, T. J. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 5537–42.

(19) Young, K.; Silver, L. L.; Bramhill, D.; Cameron, P.; Eveland, S. S.; Raetz, C. R.; Hyland, S. A.; Anderson, M. S. *J. Biol. Chem.* **1995**, *270*, 30384–91.

(20) Ruiz, N.; Falcone, B.; Kahne, D.; Silhavy, T. J. *Cell* **2005**, *121*, 307–17.

(21) Sperandio, P.; Pozzi, C.; Deho, G.; Polissi, A. *Res. Microbiol.* **2006**, *157*, 547–58.

(22) Ganzle, M. G. *Appl. Microbiol. Biotechnol.* **2004**, *64*, 326–32.

(23) Ganzle, M. G.; Vogel, R. F. *Appl. Environ. Microbiol.* **2003**, *69*, 1305–7.

(24) Bakker, E. P.; Mangerich, W. E. *J. Bacteriol.* **1981**, *147*, 820–6.

(25) Dong, S. D.; Oberthur, M.; Losey, H. C.; Anderson, J. W.; Eggert, U. S.; Pecuh, M. W.; Walsh, C. T.; Kahne, D. *J. Am. Chem. Soc.* **2002**, *124*, 9064–5.




Figure 3. Comparison between death of *B. cereus* and the membrane effects elicited by C_{12} -TA. (A) Correlation between cell death and the dissipation of $\Delta\Psi$ (\square) and (B) ΔpH (\diamond). (C) Cell death (\bullet , Y1) does not occur at concentrations needed for membrane permeabilization (\circ , Y2).

a more direct comparison of cell death to the dissipation of ΔpH and $\Delta\Psi$. Furthermore, the concentrations of C_{12} -TA needed for dissipation of ΔpH and $\Delta\Psi$ correlate well with the MIC values, suggesting membrane depolarization as the mechanism of action, rather than an artifact of artificially high antibiotic concentrations.

On the basis of our experimental data, the hydrophobicity of C_{12} -TA, and the knowledge that lipid substituted antibiotics are known to target the membranes of Gram-positive bacteria,²⁵ we reasoned that our observations may be due to a detergent-

Table 2. Activity of C_{12} -TA in Gram-Positive Bacteria^a

bacteria	death	ΔpH	$\Delta\Psi$	membrane permeation
<i>B. cereus</i> PCI 213	53.6 ± 3.7	61.6 ± 8.7	49.0 ± 2.0	293 ± 48.0
<i>B. subtilis</i> Marburg	64.5 ± 1.9	60.3 ± 16.2	23.9 ± 5.1	110 ± 12.6
<i>E. faecalis</i> NCTC 775	116 ± 26.2	17.5 ± 2.8	121 ± 6.3	$\sim 875^b$
<i>S. aureus</i> Wood 46	294 ± 33.5	15.0 ± 3.0	186 ± 6.2	$\sim 575^b$

^a All EC_{50} values are reported in μM . ^b Insufficient data to calculate an accurate EC_{50} .

Table 3. Onset of Resistance of *S. aureus* Wood 46 to C_{12} - and C_{14} -TA

passage	C_{12} -TA MIC ($\mu g/mL$)	C_{14} -TA MIC ($\mu g/mL$)
0	25	6.25
20	25	6.25

like general disintegration of the membrane as the underlying mode of action to account for C_{12} -TA cytotoxicity. The ability of C_{12} -TA to permeabilize the cell membrane was measured by incubating log phase cultures with propidium iodide (PI) and C_{12} -TA. PI, which is unable to penetrate intact membranes, will enter cells with permeabilized membranes and bind DNA to emit a fluorescent signal. Fluorescence was observed in *B. cereus* with an EC_{50} of $293 \pm 48.0 \mu M$ C_{12} -TA (Figure 3C): the high concentration needed to observe PI fluorescence indicates that membrane permeabilization is not involved in cell death, but is instead more likely a secondary effect of bacterial death. This reasoning was corroborated by measuring the ability of C_{12} -TA to kill similarly dense cultures of *B. cereus*, which occurred with an EC_{50} of $53.6 \pm 3.7 \mu M$ (Figure 3).

If the mechanism is indeed the nonspecific shuttling of ions across the bacterial membrane, then there should be no difference in the MIC values of the natural (*S*)- C_{12} -TA and the unnatural *R* form. Toward this end, we synthesized (*R*)- C_{12} -TA as described previously⁴ and evaluated its antibacterial activity against *B. cereus*, *S. aureus*, and *C. diphtheriae*. For all three species examined, there was no difference between the MIC values of (*R*)- C_{12} -TA and (*S*)- C_{12} -TA. This finding supports a nonspecific interaction, such as that suggested by the membrane depolarization data, rather than interaction of the TA compounds with an unknown specific receptor.

***S. aureus* Does Not Develop Resistance to C_{12} -TA.** To study the development of resistance to C_{12} -TA, we monitored *S. aureus* growth in the presence of subinhibitory concentrations of C_{12} -TA. These studies focused on *S. aureus* due to its relevance in human disease and the fact that it is a known competitor of *P. aeruginosa* in the lungs of CF patients. Furthermore, *S. aureus* is the pathogen most commonly associated with antibacterial resistance, and to date it has developed resistance to every antibiotic used to treat its infections.²⁶ Cultures of *S. aureus* were incubated for 24 h in the presence of varying concentrations of C_{12} -TA, and the culture just below the MIC was taken and used for subculturing in fresh growth medium containing the same range of concentrations of C_{12} -TA as before. The MIC was recorded after each passage, and, after 20 passages, there was no observed increased in the MIC of C_{12} -TA or C_{14} -TA (Table 3).

To gain further insight into the activity of C_{12} -TA against clinically relevant scenarios of bacterial infection, we also measured the capacity of C_{12} -TA to disrupt biofilms of *S.*

(26) Walsh, C. T.; Fischbach, M. A. *Angew. Chem., Int. Ed.* **2008**, *47*, 5700–2.




Figure 4. BMDM cells were treated with 50 μM 3-oxo- C_{12} -HSL (C12) or C_{12} -TA as indicated, and protein extracts were analyzed by Western blot for PARP cleavage and p38 phosphorylation (p-p38).

aureus. However, C_{12} -TA did not exhibit activity in this regard (Figure S1).

C_{12} - and C_{14} -TA Are Not Toxic to Human Cells. Collectively, these microbiological data suggest the use of tetramic acid-derived compounds as therapeutic agents against bacterial infections. As an initial step in this direction, the tetramic acids were evaluated for the ability to induce apoptosis, as well as general cytotoxic effects, in bone marrow-derived macrophage (BMDM) cells. We have previously shown that, upon 3-oxo- C_{12} -HSL stimulation, macrophages activate several intracellular signaling events, including pro- and antiapoptotic pathways. For example, activation of the antiapoptotic p38 mitogen-activated protein kinase (MAPK) is induced via the phosphorylation of p38 kinase domain.^{27,28} In turn, the pro-apoptotic effects of 3-oxo- C_{12} -HSL are mediated through the activation of caspase-9 and caspase-3, and subsequent cleavage of poly(ADP-ribose) polymerase (PARP), a biochemical marker indicative of apoptosis.^{27,29} To address whether C_{12} -TA has the same or a similar effect on mammalian cells, we investigated its effect on p38 phosphorylation (p-p38) and PARP cleavage in BMDM. In contrast to 3-oxo- C_{12} -HSL, C_{12} -TA failed to induce p-p38 and PARP cleavage, providing strong evidence that the conversion of 3-oxo- C_{12} -HSL to C_{12} -TA results in functionally distinctive biological activities of these molecules (Figure 4). Thus, it is very likely that 3-oxo- C_{12} -HSL possesses the ability to act as an agonist for both eukaryotic and prokaryotic cells, whereas action of C_{12} -TA is confined to bacterial cells. To evaluate the toxicity of C_{12} -TA against human cells, BMDM cells were treated with C_{12} - and C_{14} -TA for 22 h, and under both conditions the cells exhibited similar viability to the DMSO control even at concentrations up to 100 μM (Figure 5). However, both 3-oxo- C_{12} - and 3-oxo- C_{14} -HSL were found to be toxic, which is consistent with our previous reports.²⁷

Discussion

The past decade has seen a marked increase in the understanding of bacterial QS systems, and the various classes of QS compounds along with their effects on bacterial population




Figure 5. Viability of BMDM cells in the presence of C_{12} -TA and related compounds after 22 h incubation (legend: 1, 3-oxo- C_{12} -HSL; 2, C_{12} -TA; 3, (R)-3-oxo- C_{12} -HSL; 4, (R)- C_{12} -TA; 5, 3-oxo- C_{14} -HSL; 6, C_{14} -TA; 7, 1% DMSO; 8, control).

behavior have been investigated extensively.^{30–32} Although AHL-regulated QS in *P. aeruginosa* has become one of the best-studied systems, the capacity of 3-oxo- C_{12} -HSL to undergo a spontaneous Claisen-like cyclization to form the tetramic acid C_{12} -TA, a compound with antibacterial activity against Gram-positive and certain Gram-negative bacteria, was only recently discovered.⁴ The nonenzymatic, base-catalyzed conversion of 3-oxo- C_{12} -HSL to C_{12} -TA is also reminiscent of other bacterially produced antimicrobial agents, particularly the production of the microcin E492m by *Klebsiella pneumoniae*. The active form of this toxin is formed by an enzyme-independent, base-catalyzed rearrangement of an enzymatically produced precursor.³³ In light of these reports, the cytotoxic activity, and the resistance of *P. aeruginosa* to its own C_{12} -TA, we envision a role for C_{12} -TA both in microbial warfare as well as a scaffold for future medicinal chemistry efforts. This hypothesis is supported by clinical data, as isolation of *S. aureus* and *H. influenzae*, but not *B. cepacia*, occurs less frequently as incidences of *P. aeruginosa* increase, suggesting a competition for survival among these pathogens in the lungs of CF patients.³⁴ The selective activity of C_{12} -TA may provide one plausible explanation for these observations and the corresponding success of *P. aeruginosa* in its infections of CF patients.

The conversion of 3-oxo- C_{12} -HSL to C_{12} -TA and the antibacterial activity of C_{12} -TA are indicative of a role for AHL-based QS beyond that of strictly cell-to-cell communication.^{35,36} Several reports have described the role of 3-oxo- C_{12} -HSL in the modulation of host responses including immunomodulation

- (27) Kravchenko, V. V.; Kaufmann, G. F.; Mathison, J. C.; Scott, D. A.; Katz, A. Z.; Wood, M. R.; Brogan, A. P.; Lehmann, M.; Mee, J. M.; Iwata, K.; Pan, Q.; Fearn, C.; Knaus, U. G.; Meijler, M. M.; Janda, K. D.; Ulevitch, R. J. *J. Biol. Chem.* **2006**, *281*, 28822–30.
- (28) Kravchenko, V. V.; Kaufmann, G. F.; Mathison, J. C.; Scott, D. A.; Katz, A. Z.; Grauer, D. C.; Lehmann, M.; Meijler, M. M.; Janda, K. D.; Ulevitch, R. J. *Science* **2008**, *321*, 259–63.
- (29) Nicholson, D. W.; Ali, A.; Thornberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; et al. *Nature* **1995**, *376*, 37–43.

- (30) Deziel, E.; Lepine, F.; Milot, S.; He, J.; Mindrinos, M. N.; Tompkins, R. G.; Rahme, L. G. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 1339–44.
- (31) Lazdunski, A. M.; Ventre, I.; Sturgis, J. N. *Nat. Rev. Microbiol.* **2004**, *2*, 581–92.
- (32) Venturi, V. *FEMS Microbiol. Rev.* **2006**, *30*, 274–91.
- (33) Nolan, E. M.; Fischbach, M. A.; Koglin, A.; Walsh, C. T. *J. Am. Chem. Soc.* **2007**, *129*, 14336–47.
- (34) Cystic Fibrosis Foundation, Bethesda, MD, 2005.
- (35) Schertzer, J. W.; Boulette, M. L.; Whiteley, M. *Trends Microbiol.* **2009**, *17*, 189–95.
- (36) Cooley, M.; Chhabra, S. R.; Williams, P. *Chem. Biol.* **2008**, *15*, 1141–7.

and the induction of apoptosis.^{27,37,38} These effects have led to a hypothesized role of 3-oxo-C₁₂-HSL in the establishment of *P. aeruginosa* infections by modulating the responses of the host. In a similar fashion, 3-oxo-C₁₂-HSL, through the action of C₁₂-TA, may also aid in the establishment of infection by inhibiting the growth of competing bacteria. Similar studies have suggested the role of *P. aeruginosa* in the selection of antibiotic resistant strains of *S. aureus* through the function of a 2-alkyl-4-quinolone, a class of molecules also involved in the interspecies communication of *P. aeruginosa*.³⁹ As such, it is evident that *P. aeruginosa* possesses a host of mechanisms to mediate interspecies competition. From our results, we believe that C₁₂-TA has a place in this arsenal, and, accordingly, it is likely that QS systems play a larger role in bacterial communities than was previously recognized. Indeed, it is a plausible scenario in which *P. aeruginosa* produces one molecule, 3-oxo-C₁₂-HSL, to mediate competition with both host cells and bacterial competitors in that 3-oxo-C₁₂-HSL exerts its effects primarily on host cells and the rearranged product C₁₂-TA primarily acting on bacterial competitors.

Given the broad spectrum of cytotoxic effects, C₁₂-TA also represents a potential lead compound for the development of antimicrobial therapeutics. Indeed, medicinal chemistry efforts have recently been directed toward the development of N-substituted tetramic acids as antibiotics.^{40,41} While these TA derivatives exhibited excellent potency against many Gram-positive bacteria, they exhibited no activity against Gram-negative pathogens, moderate activity against *M. tuberculosis*, and toxic effects against mammalian cells, all of which are in contrast with the activity of C₁₂- and C₁₄-TA. Despite the somewhat modest antibacterial activity of C₁₂-TA, it is likely that little evolutionary pressure exists to optimize the C₁₂-TA structure based on the fact that it may be used by *P. aeruginosa* to gain a competitive advantage, rather than the complete elimination of competitors. *P. aeruginosa* does not necessarily stand to gain from optimization of the C₁₂-TA structure, as it is derived from an autoinducer that has been optimized for *P. aeruginosa* communication and possibly for interaction with host innate immunity. This is further supported by the observation that there was no decrease in the efficacy of C₁₂- or C₁₄-TA against *S. aureus* in a resistance development assay. Another important consideration in the identification of lead compounds is the capacity of the molecule to exist in biological settings, and, indeed, C₁₂-TA has been detected in cultures of *P. aeruginosa*.⁴ Thus, C₁₂-TA may represent the balance of activity and biocompatibility characteristic of small molecule natural product drug targets.⁴² Based on these studies of C₁₂-TA, which upon further elucidation of its antibacterial activity implicates its role in the survival of *P. aeruginosa*, the discovery of new AHL-derived TAs may represent an exciting new avenue in the study of interspecies bacterial interactions as a whole, as

all organisms that produce 3-oxo-AHLs for communication purposes may also benefit from the conversion to TA-derived molecules.

Experimental Section

Antibacterial Activity of C₁₂-TA. The following bacterial strains were purchased from the American type Culture Collection (ATCC) unless otherwise stated: *Bacillus cereus* ATCC 11778, *B. anthracis* Ames strain (Dr. R. Ulrich), *B. subtilis* ATCC 6051, *Enterococcus faecalis* ATCC 29212, *Staphylococcus aureus* ATCC 25923, *S. aureus* USA-300 clone (Network on Antimicrobial Resistance in *Staphylococcus aureus*, NARSA), *L. plantarum* ATCC BAA-793, *Corynebacterium diphtheriae* ATCC 13812, *M. tuberculosis* ATCC 27294 (Dr. C. Barry), *V. cholerae* TP (Prof. D. Bartlett), *V. cholerae* ATCC 39315, *V. harveyi* ATCC BAA-1116, *H. influenzae* ATCC 49401, *B. cepacia* ATCC 25416, *E. coli* D22, *E. coli* Δ imp (Prof. F. Romesberg), and *E. coli* ATCC 25404. A bacterial colony was picked and grown overnight in the growth medium and at the temperature recommended by ATCC. For MIC determinations, all bacteria were grown in Mueller Hinton broth except for *M. tuberculosis* (iron deficient GAST medium⁴³), *V. harveyi* (AB medium), *L. plantarum* (Difco Lactobacilli MRS broth), and *V. cholerae* (LB medium). On the next day, the culture was diluted to $\sim 1 \times 10^4$ CFU/mL. Aliquots (198 μ L) were added into a 96-well microtiter plate containing the test compound dissolved in a DMSO/water solution for a final DMSO concentration of 0.05%. The microtiter plate was sealed (BreatheEasy, Research Products International) and incubated on a shaker at the appropriate temperature overnight. The next day, OD₆₀₀ was measured by using a ThermoMax plate reader (Molecular Devices). EC₅₀ values were determined by nonlinear curve-fitting using Kaleidagraph 3.6.2 (Synergy Software), and MIC values were determined by visual examination of the wells for turbidity. Reported values are the average of a minimum of three replicates.

Bactericidal Assay. The following bacterial strains were purchased from the American type Culture Collection (ATCC): *Bacillus cereus* ATCC 11778, *Bacillus subtilis* ATCC 6051, *Enterococcus faecalis* ATCC 29212, and *Staphylococcus aureus* ATCC 25923. Bactericidal activity was assessed using the BacTiter-Glo Microbial Cell Viability Assay kit available from Promega (Madison, WI). Briefly, cells of an overnight culture were harvested and resuspended to an OD₆₀₀ of 0.4 in fresh growth medium as recommended by ATCC. The cells were then incubated with varying concentrations of C₁₂-TA in 96-well plate format for 1 h (100 μ L per well), at which time 100 μ L of BacTiter-Glo Reagent was added to each well. Luminescence was measured using a SpectraMax Gemini EM (Molecular Devices, Sunnyvale, CA) plate reader, and values were plotted and analyzed using the program Kaleidagraph (Synergy Software, Reading, PA).

Dissipation of the Transmembrane Potential ($\Delta\Psi$). Perturbations of the $\Delta\Psi$ were measured using the cationic fluorescent probe 3,3'-dipropylthiadicarbocyanine iodide (DiSC₃(5)) from Molecular Probes (Eugene, OR) as described previously.⁴⁴ Cells were cultured to an OD₆₀₀ of 0.4 in the growth medium recommended by ATCC and washed twice with potassium phosphate buffer (pH 7.0) containing 10 mM glucose. The cells were resuspended in the same buffer containing 5 μ M DiSC₃(5) and incubated for 15 min, or until a steady signal was achieved, at the appropriate temperature. After this time, the suspension was transferred to a 96-well plate (200 μ L per well) containing 2 μ L (in DMSO) of the test compound in each well. Fluorescence was measured (λ_{exc} 643 nm, λ_{em} 665 nm) over 20 min using a SpectraMax Gemini EM (Molecular Devices) fluorescence plate reader.

(37) Telford, G.; Wheeler, D.; Williams, P.; Tomkins, P. T.; Appleby, P.; Sewell, H.; Stewart, G. S.; Bycroft, B. W.; Pritchard, D. I. *Infect. Immun.* **1998**, *66*, 36–42.

(38) Wagner, V. E.; Frelinger, J. G.; Barth, R. K.; Iglewski, B. H. *Trends Microbiol.* **2006**, *14*, 55–8.

(39) Hoffman, L. R.; Deziel, E.; D'Argenio, D. A.; Lepine, F.; Emerson, J.; McNamara, S.; Gibson, R. L.; Ramsey, B. W.; Miller, S. I. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 19890–5.

(40) Yendapally, R.; Hurdle, J. G.; Carson, E. I.; Lee, R. B.; Lee, R. E. *J. Med. Chem.* **2008**, *51*, 1487–91.

(41) Hurdle, J. G.; Yendapally, R.; Sun, D.; Lee, R. E. *Antimicrob. Agents Chemother.* **2009**, *53*, 4028–31.

(42) Wilson, R. M.; Danishefsky, S. J. *J. Org. Chem.* **2006**, *71*, 8329–51.

(43) De Voss, J. J.; Rutter, K.; Schroeder, B. G.; Su, H.; Zhu, Y.; Barry, C. E., 3rd. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 1252–7.

Dissipation of the Transmembrane Proton Gradient (ΔpH).

Internal pH was monitored according to the procedure developed by Breeuwer et al.⁴⁵ In short, cells of an overnight culture were washed and resuspended in 50 mM HEPES buffer (pH 8.0) to an OD_{600} of 0.4. Carboxyfluorescein diacetate succinimidyl ester (cFDA-SE, final concentration 1 μM) was added to the suspension, followed by incubation for 10 min at the appropriate temperature. The cells were washed and resuspended in 50 mM potassium phosphate buffer (pH 7.0), and 10 mM glucose was added to eliminate nonconjugated cFDA-SE. After incubation for 30 min at the appropriate temperature, cells were washed twice with potassium phosphate buffer (pH 6.5) containing 10 mM glucose. The cells were resuspended in the same buffer and transferred to a 96-well plate containing the test compound, as in the $\Delta\Psi$ assay. Assays were performed and fluorescence was measured over 20 min using the fluorescence plate reader with excitations of 440 and 490 nm and an emission of 525 nm.⁴⁵ The ratio of signals (490:440) was plotted as a function of concentration and analyzed using Kaleidagraph.

Membrane Permeation Assay. Membrane permeation was assayed by determination of the permeability of the cell membranes to propidium iodide (PI). Cells of an overnight culture were washed twice with 50 mM potassium phosphate buffer (pH 6.5) and resuspended in the same buffer containing 13 μM PI. Membrane permeation was then monitored by the measurement of fluorescence (λ_{exc} 488/ λ_{em} 617) upon incubation of cells with varying concentrations of C_{12} -TA in 96 well plate format, as in the previous two assays.

Determination of Resistant Bacteria. Culture tubes containing BHI medium and C_{12} -TA were inoculated with an overnight culture of *S. aureus* to obtain 1×10^4 cfu/mL. The concentrations of C_{12} -TA ranged from three doubling dilutions above and below the previously measured MIC. The cultures were incubated for 24 h at 37 °C, and the culture incubated with a concentration of TA one dilution step below the MIC was used as the inoculum for the next transfer (1×10^4 cfu/mL). The process was then repeated 19 times for a total of 20 passages, with MIC measured as before.

Mammalian Cell Studies. Bone marrow-derived macrophages (BMDM) were prepared from C57BL/6 mice by using standard

protocols. BMDM were cultured in 70% growth medium [Dulbecco's modified Eagle's medium (4.5 g/L glucose) supplemented with 10% fetal bovine serum (HyClone), L-glutamine, pyruvate, penicillin/streptomycin, and nonessential amino-acids] and 30% L929 condition medium as described.²⁷

Cytotox Assay. Cytotoxicity of test compounds was assessed using bone marrow-derived macrophages (BMDM) and a solution assay based on the reduction of MTS into formazan (Promega) according to the manufacturer's protocol. BMDM were cultured according to standard techniques in 70% growth medium (Dulbecco's modified Eagle medium (4.5 g/L glucose) supplemented with 10% fetal bovine serum, 100 mM HEPES, 5 mM sodium pyruvate, L-glutamine, penicillin/streptomycin, and nonessential amino acids) and 30% L929 conditioned medium. In brief, cells were allowed to recover for 24 h after transfer to the assay plate, and medium was refreshed prior to the assay. Compounds were added directly from DMSO stocks to a final DMSO concentration of 1%, and cells were incubated at 37 °C, 5% CO_2 for 24 h before addition of the MTS substrate. Absorbance was measured after 3 h incubation at 490 nm, and data were normalized to untreated controls. All experiments have been performed in triplicate.

Acknowledgment. We thank Professor Michael Gänzle of the University of Alberta, Edmonton, AB, Canada, for generously providing us with reutericyclin, and Prof. Floyd Romesberg for providing the mutant *E. coli* strains. The following isolate was obtained through the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) Program: *Staphylococcus aureus* USA300 (NRS384), supported under NIAID/NIH contract no. HHSN272200700055C. We would also like to thank Prof. Bastiaan P. Krom of the University of Groningen for critical reading of the manuscript. This work was supported by the National Institutes of Health (AI079503 to K.D.J., AI080715 to G.F.K., AI079436 to V.V.K.), the Skaggs Institute for Chemical Biology, and a Sanofi-Aventis Graduate Fellowship (C.A.L.), and in part by the Intramural Research program of the NIAID, NIH.

Supporting Information Available: Synthetic procedures, spectral data, and biofilm protocols. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA9056079

(44) Wu, M.; Maier, E.; Benz, R.; Hancock, R. E. *Biochemistry* **1999**, *38*, 7235–42.

(45) Breeuwer, P.; Drocourt, J.; Rombouts, F. M.; Abee, T. *Appl. Environ. Microbiol.* **1996**, *62*, 178–183.